Five Key Reasons to Attend SMi's 21st Annual Pain Therapeutics Conference

LONDON - Amzeal -- Convening on the 10th and 11th of May 2021, SMi Group are delighted to host its 21st Annual Pain Therapeutics Conference which will provide insights into cutting edge drug discovery science, preclinical development trends and will explore novel pain drug targets and novel biomarkers. It will also explore how COVID-19 has changed the experience of clinical trials and presented an opportunity to reform approach to data verification, analysis, collection and more.

Interested parties can join the conference at by visiting www.pain-therapeutics.co.uk/pr2

With a strong programme and an expert speaker line-up, SMi Group share the top five key reasons to join the conference:
1. Astrazeneca opening address – Clinical Development on Ostroarthiritis

More on Amzeal News

• Concerned Citizens of South Central Los Angeles Send Open Letter To Biden Administration
• Footprint Project Partners with Clean Energy Leaders to Deploy Solar Energy Storage to Texas for Winter Storm Recovery
• Sandline Global Fortifies World-Class Executive Team: Glenn Hopper Joins as Chief Financial Officer
• RSTOR Enhances Software Defined Cloud Platform to Support Hybrid, Multi-Cloud Enterprise Infrastructures
• GBKSOFT reveals the benefits of Building Websites with PHP in 2021?

Update: Demonstration of significant pain relief in subjects with painful osteoarthritis of the knee with a novel anti NGF, anti-TNFa bispecific fusion protein
Presented by Iain Chessell, Global Head of Neuroscience, BioPharmaceuticals Research & Development from AstraZeneca

2. National Institutes of Health Spotlight Session – Expansion of Pain Research
Exploring the expansion of pain research at the National Institutes of Health
Presented by David Thomas, Senior Advisor National Institutes of Health

3. Biomarker Presentation from Collegium Pharmaceuticals
Where have we been and where should we go? Evaluating the role and development of Biomarkers.
Presented by Richard Malamaut, Chief Medical Officer & EVP at Collegium Pharmaceuticals

4. Novaremed's Deep Dive Session – Diabetic Neuropathic Pain
Exploring Novaremed's work in developing NRD.E1, an innovative therapy for diabetic neuropathic pain
Presented by Sara Mangialaio, Head of Research & Development and Chief Medical Officer at Novaremed

More on Amzeal News

• Syxsense Announces Integration with Microsoft Office 365
• Launch of Trace One E-Sourcing Will Boost Retailers' Private Label Speed to Market
• Australian Content Farm Kantado gets its first US hit single
• New Video Streaming Startup, Relax Scenes, Launches Indiegogo Campaign to Support Their Expansion
• Bronx DWI Lawyer Announces New Website

5. Virtual Conference: Online Access Only
Live and On Demand speaker content: Get access to the latest strategies and case studies from your marketplace online.
Network with all the event attendees: Connect, see who is attending, chat and share contact details with all online delegates, speakers and sponsors
Host & Join Meetings & Socials: Join preferred speaking sessions, host meetings and even a virtual Networking social, with in built Zoom functionality

The full agenda, speaker line-up and brochure can be viewed online at: www.pain-therapeutics.co.uk/pr2

Sponsored by: Transpharmation and MD Biosciences

To join as a sponsor/exhibitor, please get in touch with Alia Malick, Director on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6162 or ssapal@smi-online.co.uk

SMi's 21st Annual Pain Therapeutics Conference
10–11 May 2021
Virtual Conference: Online Access Only
www.pain-therapeutics.co.uk/pr2
#SMiPain